Wall Street analysts expect BioScrip Inc (NASDAQ:BIOS) to announce $185.73 million in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for BioScrip’s earnings, with estimates ranging from $185.46 million to $186.00 million. BioScrip posted sales of $175.79 million in the same quarter last year, which suggests a positive year-over-year growth rate of 5.7%. The firm is expected to report its next quarterly earnings report on Tuesday, August 6th.
On average, analysts expect that BioScrip will report full year sales of $752.83 million for the current fiscal year, with estimates ranging from $752.66 million to $753.00 million. For the next year, analysts expect that the firm will post sales of $802.56 million, with estimates ranging from $796.00 million to $809.11 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover BioScrip.
BioScrip (NASDAQ:BIOS) last posted its earnings results on Thursday, May 2nd. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The business had revenue of $178.96 million during the quarter, compared to the consensus estimate of $179.23 million. During the same quarter last year, the firm earned ($0.12) earnings per share. The business’s quarterly revenue was up 6.2% on a year-over-year basis.
Shares of BioScrip stock traded down $0.03 during trading hours on Monday, reaching $2.03. The company’s stock had a trading volume of 13,415 shares, compared to its average volume of 1,341,307. BioScrip has a one year low of $1.56 and a one year high of $4.14. The company has a market cap of $263.95 million, a PE ratio of -4.13 and a beta of 0.66.
A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its position in BioScrip by 28.8% in the 4th quarter. BlackRock Inc. now owns 9,807,734 shares of the company’s stock valued at $35,013,000 after buying an additional 2,191,490 shares during the period. Vanguard Group Inc boosted its position in BioScrip by 0.5% in the 3rd quarter. Vanguard Group Inc now owns 5,987,679 shares of the company’s stock valued at $18,562,000 after buying an additional 27,904 shares during the period. Vanguard Group Inc. boosted its position in BioScrip by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 5,987,679 shares of the company’s stock valued at $18,562,000 after buying an additional 27,904 shares during the period. Rothschild & Co. Asset Management US Inc. boosted its position in BioScrip by 68.1% in the 1st quarter. Rothschild & Co. Asset Management US Inc. now owns 3,812,471 shares of the company’s stock valued at $7,625,000 after buying an additional 1,545,050 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in BioScrip by 7.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,617,021 shares of the company’s stock valued at $9,342,000 after buying an additional 180,389 shares during the period. 82.29% of the stock is owned by institutional investors.
BioScrip Company Profile
BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.
Read More: Penny Stocks, Risk and Reward Factors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.